EUnetHTA Magazine Summer 2021 – now available

We are pleased to publish the EUnetHTA Magazine for Summer 2021, the last issue of Joint Action 3 (2016-2021). While the magazine is intended to publish on a quarterly basis, the changes we have all experienced over the past year and a half have, understandably, presented a challenge to generating articles while our ‘regular’ workflows […]

PTJA16 – Venetoclax in combination with an hypomethylating agent for treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy – final assessment now available

This is the pharmaceutical Joint Assessment PTJA16 – Venetoclax with a hypomethylating agent fort he treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. In June, 2021, the European Commission granted marketing authorisation for Venclyxto® (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid […]

EUnetHTA and EMA take stock of their cooperation

The European Network for Health Technology Assessment (EUnetHTA) and the European Medicines Agency (EMA) have published a Technical Report on their achievements since 2017.   The report covers the latest phase of an open and successful collaboration that began in 2010, and demonstrated that the synergies between regulatory evaluation and health technology assessment (HTA) along […]

OTCA27 – Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)- final report now available

The final report is now available for the Relative Effectiveness Assessment OTCA27 “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)”. The aim of this multi-technology HTA was to assess 21 minimally invasive surgical treatments for benign prostatic hyperplasia (BPH), either comparing minimally invasive treatments to each other or […]

Patient group input requested for new Rapid Reviews on medicinal products for COVID-19.

EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]

EUnetHTA – Open Letter of Comment

This is an open letter, written by the Chair of the EUnetHTA Executive Board, Niklas Hedberg. It expresses commentary on the role of EUnetHTA within European HTA, and that of scientific journals. Please access the letter here: EUnetHTA – Open Letter of Comment For any questions regarding this, please contact the EUnetHTA Secretariat team at eunethta@zinl.nl

RCROT02 – Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19 – report now available

EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19” is now available. This is the second rapid review assessing health technologies for SARS-CoV-2. The objective of this assessment was to identify, assess and summarise evidence on […]

PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older – Final assessment now available

This is the pharmaceutical Joint Assessment PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. In October, 2020, the European Commission granted conditional marketing authorisation for Adakveo® (crizanlizumab) for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. Publication of […]

PTRCR18 – Dexamethasone for the treatment of hospitalised patients with COVID-19 – Final Rapid Collaborative Review now available.

This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen or mechanical venilation. This Rapid Collaborative Review aims to define, according to the national […]

Patient group input requested for a new Joint Assessment on a medicinal product for cerebral adrenoleukodystrophy (CALD).

This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen or mechanical venilation. This Rapid Collaborative Review aims to define, according to the national […]